References

Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis. 1993;17(1):109-113.

Arias L, Lebbos JM, Lyons J; Decision Resources. Hospital anti-infectives insight series: Clostridium difficile. http://decisionresources.com/Products-and-Services/Report?r=haisxx0809. Published August 2009. Accessed June 3, 2011.

Blondeau, JM. What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhea? J Antimicrob Chemother. 2009;63:238–242.

Centers for Disease Control and Prevention. Clostridium difficile (CDI) infections toolkit. 2009. http://www.cdc.gov/HAI/pdfs/toolkits/CDItoolkitwhite_clearance_edits.pdf. Published December 23, 2009. Accessed May 21, 2011.

Centers for Disease Control and Prevention. FAQs (Frequently Asked Questions) about Clostridium Difficile. Available at: http://www.cdc.gov/ncidod/dhqp/pdf/guidelines/Cdiff_tagged.pdf. Accessed June 22, 2011.

Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431-455.

Chamorro RM, Blanch RS, Vidal MJM, et al. Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil. Clin Transl Oncol. 2005;7(6):258-261.

DIFICID [package insert]. San Diego, CA: Optimer Pharmaceuticals®, Inc; March 2013.

Dorland’s Online Medical Dictionary. Elsevier. Accessed June 3, 2011.

Elixhauser A, Jhung M. Clostridium difficile-associated disease in U.S. hospitals, 1993-2005. HCUP Statistical Brief #50. Rockville, MD: Agency for Healthcare Research and Quality, Centers for Disease Control and Prevention; April 2008.

Flagyl® [package insert]. New York, NY: Pfizer Inc; April 2010.

Food and Drug Administration Center for Drug Evaluation and Research Advisory Committee for Pharmaceutical Science and Clinical Pharmacology. Bioequivalence (BE) recommendation for vancomycin HCI tablets. August 4, 2009.

Hu MY, Katchar K, Kyne L, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology. 2009;136(4):1206-1214.

Infectious Diseases Society of America. http://www.idsociety.org/Index.aspx. Accessed October 10, 2011.

Laffan AM, Bellantoni MF, Greenough WB, Zenilman JM. Burden of Clostridium difficile-associated diarrhea in a long-term care facility. J Am Geriatr Soc. 2006;54:1068–1073.

Levine, Donald P. Vancomycin: a history. Clin Infect Dis. 2006;42:S5–S12.

McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Eng J Med. 2005;353(23):2433-2441.

Miller M, Gravel D, Mulvey M, et al; for Canadian Nosocomial Infection Surveillance Program. Health care–associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis. 2010;50(2):194-201.

Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility – associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol. 2011;32(4):387-390.

National Center for Biotechnology Information. http://www.ncbi.nlm.nih.gov/. Accessed October 10, 2011.

Neidhardt FC. The bacteria cell: structures for growth, survival, and colonization. In: Sherris JC, ed. An Introduction to Infectious Diseases. 2nd ed. New York, NY: Elsevier; 1990:11-26.

Onderdonk AB, Garrett WS. Gas gangrene and other Clostridium-associated diseases. In: Mandell GL, Bennett, JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Churchill Livingstone; 2009:3103-3109.

Orange Book: approved drug products with therapeutic equivalence evaluations. http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=050606&TABLE1=OB_Rx. Accessed August 29, 2011.

Petrin D, Delgaty K, Bhatt R, Garber G. Clinical and microbiological aspects of trichomonas vaginalis. Clin Microbiol Rev. 1998;11(2):300-317.

Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009;7(7):526-536.

Society for Healthcare Epidemiology of America. http://www.shea-online.org/. Accessed October 10, 2011.

Tamara Myers, ed. Mosby’s Medical Dictionary. St. Louis, Missouri: Mosby Elsevier; 2009.

Thielman NM, Wilson KH. Chapter 96: Antibiotic-Associated Colitis. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennet’s Principles and Practice of Infectious Diseases. Chapter 96. 7 ed. Churchill Livingstone Elsevier; 2009.

Thomas DR, Bennett RG, Laughon BE, et al. Postantibiotic colonization with Clostridium difficile in nursing home patients. J Am Geriatr Soc. 1990;38:415-420.

TRICARE. http://www.tricare.mil/mybenefit/. Accessed October 10, 2011.

Vancocin® (vancomycin hydrochloride capsules, USP) [package insert]. Exton, PA: ViroPharma Incorporated. December 2011.

Important Safety Information

  • DIFICID is contraindicated in patients with hypersensitivity to fidaxomicin
  • DIFICID should not be used for systemic infections
  • Acute hypersensitivity reactions (angioedema, dyspnea, pruritus, and rash) have been reported. In the event of a severe reaction, discontinue DIFICID.
  • Only use DIFICID for infection proven or strongly suspected to be caused by C. difficile.
    Prescribing DIFICID in the absence of a proven or strongly suspected C. difficile infection is unlikely to provide benefit to the patient and increases the risk of the development of drug- resistant bacteria.
  • The most common adverse reactions reported in clinical trials are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%), and neutropenia (2%)

Indication and Usage

  • DIFICID is a macrolide antibacterial drug indicated in adults ≥ 18 years of age for treatment of Clostridium difficile-
    associated diarrhea
  • To reduce the development of drug-resistant bacteria and maintain the effectiveness of DIFICID and other
    antibacterial drugs, DIFICID should be used only to treat infections that are proven or strongly suspected
    to be caused by Clostridium difficile

Please click here for full prescribing information for DIFICID